BCL2 and ovarian cancer: The BCL2 protein promotes cell survival by inhibiting programmed cell death or apoptosis.10,11 A variety of chemoresistant carcinomas, including ovarian cancer, uterine cancer, breast cancer, and gastric cancer, express BCL2, suggesting that BCL2 may interfere with a variety of cytotoxic agents, including platinum.12,13 The most commonly used form of chemotherapy, paclitaxel,14 is utilized in curative protocols in different types of cancer, with differing levels of response to treatment.